Literature DB >> 1615494

Procoagulant activity in bronchoalveolar fluids: no relationship with tissue factor pathway inhibitor activity.

P de Moerloose1, E De Benedetti, L Nicod, C Vifian, G Reber.   

Abstract

Abnormalities in local coagulation may explain alveolar fibrin deposition which often accompanies human lung injuries. The purpose of this study was to investigate the generation of procoagulant activity (PCA) and tissue factor pathway inhibitor (TFPI) in selected bronchoalveolar lavage fluids (BAL) from controls (n = 7) and from patients with interstitial lung diseases (n = 9), Pneumocystis carinii (PCP) pneumonia (n = 11) and bacterial pneumonia (n = 8). As compared with controls a significant increase of PCA was observed in the three groups with lung diseases. PCA in BAL from patients with untreated interstitial lung diseases (PC Units mean of 162 +/- 48) was significantly higher than PCA of treated patients (PC Units 36 +/- 10; p less than 0.05). Increases of PCA paralleled protein levels in BAL and the protein/albumin ratios were comparable in the four groups. TFPI was significantly increased in PCP (p less than 0.02) and bacterial pneumonia (p less than 0.03), but only marginally increased in interstitial lung diseases when compared with controls. No correlation was found between TFPI and PCA in any of the four groups. These data indicate that increased procoagulant activity observed in various lung diseases is not counterbalanced by TFPI.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1615494     DOI: 10.1016/0049-3848(92)90202-l

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  5 in total

1.  Endogenous tissue factor pathway inhibitor has a limited effect on host defence in murine pneumococcal pneumonia.

Authors:  Florry E van den Boogaard; Cornelis van 't Veer; Joris J T H Roelofs; Joost C M Meijers; Marcus J Schultz; George J Broze; Tom van der Poll
Journal:  Thromb Haemost       Date:  2015-04-02       Impact factor: 5.249

2.  Local activation of coagulation and inhibition of fibrinolysis in the lung during ventilator associated pneumonia.

Authors:  M J Schultz; J Millo; M Levi; C E Hack; G J Weverling; C S Garrard; T van der Poll
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

Review 3.  Nebulized anticoagulants in lung injury in critically ill patients-an updated systematic review of preclinical and clinical studies.

Authors:  Jenny Juschten; Pieter R Tuinman; Nicole P Juffermans; Barry Dixon; Marcel Levi; Marcus J Schultz
Journal:  Ann Transl Med       Date:  2017-11

4.  Intra-alveolar tissue factor pathway inhibitor is not sufficient to block tissue factor procoagulant activity.

Authors:  Julie A Bastarache; Ling Wang; Zhengming Wang; Kurt H Albertine; Michael A Matthay; Lorraine B Ware
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-02-29       Impact factor: 5.464

5.  Feasibility and Safety of Local Treatment with Recombinant Human Tissue Factor Pathway Inhibitor in a Rat Model of Streptococcus pneumoniae Pneumonia.

Authors:  Florry E van den Boogaard; Jorrit J Hofstra; Cornelis van 't Veer; Marcel M Levi; Joris J T H Roelofs; Tom van der Poll; Marcus J Schultz
Journal:  PLoS One       Date:  2015-05-18       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.